A practical reference on 研究代号: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Analysis of Proteins Using Immunoprecipitation at ufl.edu Immunoprecipitation at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Chromatin+immunoprecipitation at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Introduction to Immunoprecipitation Methodology Co-Immunoprecipitation (Co-IP) Technical
== Current issues == There are various usages of ethanol which include an additive to gasoline, a primary ingredient for food preservation as well as alcoholic beverages and being used for transdermal drug delivery. For example, it can function as an antiseptic in topical creams to kill bacteria by denaturing proteins. Ethanol is an amphiphilic molecule meaning that it has chemical and physical properties associated with hydrophobic and hydrophilic molecules. Although, studies show that when penetrating through the biomembrane its hydrophobic abilities appear to be limited based on its preference to bind closely to the hydrophilic region of the phospholipids. There are various issues presented in regards to ethanol's ability to penetrate through the biomembrane and cause a reorganization of the phospholipids towards non-lamellar phases. The issues are: 1) how the alteration of the phospholipids' phase occurs 2) understanding the significance of ethanol's interaction with membrane proteins and membrane phospholipids 3) understanding the permeability of the biomembrane based on the tolerance and adaptation level in the presence of ethanol although this process appears to be concentration-dependent 4) determining the significance of ethanol's amphiphilic character as it relates to its ability to partition throughout the membrane by increasing the fluidity of it. Ethanol's hydrophobic properties are limited and primarily binds close the hydrophilic region of the phospholipid.
Following the message of the Matazetas to eradicate the Knights Templar Cartel in the state of Michoacán, 21 bodies were found throughout several municipalities of the state as of 12 April 2012. At the location of the executions, authorities discovered cardboard signs written by CJNG.
Emission of gaseous and volatile alkanes such as ethane, pentane, and hexane by plants has also been documented at low levels, though they are not generally considered to be a major component of biogenic air pollution. Edible vegetable oils also typically contain small fractions of biogenic alkanes with a wide spectrum of carbon numbers, mainly 8 to 35, usually peaking in the low to upper 20s, with concentrations up to dozens of milligrams per kilogram (parts per million by weight) and sometimes over a hundred for the total alkane fraction. Alkanes are important as pheromones, chemical messenger materials, on which insects depend for communication. 7-methyltricosane and 9-methyltricosane are active for ladybird beetles (Adalia bipunctata). The emerald ash borer (Agrilus planipennis Fairmaire) responds to 9-methylpentacosane. Female Asian long-horned beetles Anoplophora glabripennis, which are very damaging, secrete 2-methyldocosane. Waggle-dancing honey bees produce and release two alkanes, tricosane and pentacosane.
Sources: en.wikipedia.org
== History == Setmelanotide was invented at Ipsen. It was initially known as BIM-22493 and then as RM-493 and IRC-022493. It was evaluated in two one-year clinical studies. The first study enrolled 10 participants with obesity and confirmed or suspected POMC or PCSK1 deficiency while the second study enrolled 11 participants with obesity and confirmed or suspected LEPR deficiency; all participants were six years or older. Most participants had lost more than 10% of their initial body weight after a year of treatment. Some participants also reported feeling less hungry. The U.S. Food and Drug Administration (FDA) granted the application for setmelanotide orphan disease designation, breakthrough therapy designation, and priority review. The FDA granted the approval of Imcivree to Rhythm Pharmaceutical, Inc.
Silica gel may be doped with a moisture indicator that gradually changes its color when it transitions from the anhydrous (dry) state to the hydrated (wet) state. Common indicators are cobalt(II) chloride and methyl violet. Cobalt (II) chloride is deep blue when dry and pink when wet, but it is toxic and carcinogenic, and was reclassified by the European Union in July 2000 as a toxic material. Methyl violet may be formulated to change from orange to green, or orange to colorless. It also is toxic and potentially carcinogenic, but is safe enough to have medicinal uses. Ferric and ferrous salts, sometimes combined with small amounts of sodium hydroxide, provide a better alternative. In particular, ferric sulfate and double salts like ammonium iron(III) sulfate (iron alum), ammonium iron(II) sulfate, and potassium iron(III) sulfate all result in a color change from amber/yellow when dry to colorless/white when saturated.
Each facility operating an x-ray unit shall have sufficient personnel with appropriate expertise. The person responsible for radiation protection or one or more Radiation Safety Officers shall have appropriate qualifications, which shall be regularly updated. X-ray examinations may be technically performed by any other staff member of a medical or dental practice if they are under the direct supervision and responsibility of the person responsible and if they have knowledge of radiation protection. This knowledge of radiation protection has been required since the amendment of the X-ray Ordinance in 1987; medical and dental assistants (then called medical assistants or dental assistants) received this additional training in 1990. The regulations for the specialty of radiology were tightened by the Radiation Protection Act, which came into force on October 1, 2017. The handling of radioactive substances and ionizing radiation (if not covered by the X-ray Ordinance) is regulated by the Radiation Protection Ordinance (StrlSchV). Section 30 StrlSchV § 30 StrlSchV (in German) defines the "Required expertise and knowledge in radiation protection".
== Conservation == Parmotrema perlatum has been identified as a species of concern in some regions due to its rarity and declining populations. In Hungary, it has been proposed for 'endangered' status in the Hungarian lichen red list, reflecting its limited distribution and the pressures it faces in its natural habitats there. Similarly, in Ukraine, the species is listed in the Red Data Book of Ukraine with the status of "Rare". Additionally, Parmotrema perlatum is red-listed in Sweden In northern North America, its NatureServe conservation status is designated as "G4", meaning "apparently secure" at the global level. In the United States, it has been assessed as secure in Kentucky and presumed extirpated in Wisconsin, while in Canada, it is considered as vulnerable in British Columbia and Ontario, and critically imperiled in New Brunswick.
== Awards and honours == 2004 CWA Ian Fleming Steel Dagger Award shortlist for Dead I Well May Be 2007 Audie Award for Best Thriller/Suspense for The Dead Yard. 2008 Young Hoosier Award and Beehive Award shortlist for The Lighthouse Land 2009 World Book Day Award longlist for The Bloomsday Dead 2010 Spinetingler Award for Best Novel for Fifty Grand 2011 Theakston Old Peculier Crime Novel of the Year Award longlist for Fifty Grand 2013 Spinetingler Award for Best Crime Novel for The Cold Cold Ground 2013 Prix Du Meilleur Polar shortlist for The Cold Cold Ground 2013 Crime Fest Last Laugh Award shortlist for The Cold Cold Ground 2013 Ned Kelly Award for Best Crime Novel shortlist for I Hear the Sirens in the Street 2014 Barry Award (for crime novels)for Best Mystery Novel (Paperback Original) for I Hear the Sirens in the Street 2014 Grand Prix de Littérature Policière shortlist for I Hear the Sirens in the Street 2014 Theakston Old Peculier Crime Novel of the Year Award shortlist for I Hear the Sirens in the Street 2014 Ned Kelly Award for Best Fiction for In the Morning I'll Be Gone 2015 Audie Award For Best Thriller shortlist for In the Morning I'll Be Gone 2015 Prix SNCF Du Polar shortlist for The Cold Cold Ground 2015 Ned Kelly Award shortlist for Gun Street Girl 2015 Boston Globe Best Book of 2015 for Gun Street Girl 2015 Irish Times Best Crime Novel of 2015 for Gun Street Girl 2016 Edgar Award (Best Paperback Original) shortlist for Gun Street Girl 2016 Anthony Award (Best Paperback Original) shortlist for Gun Street Girl 2016 Audie Award for Best Mystery shortlist for Gun Street Girl 2016 Boston Globe Best Book of 2016 for Rain Dogs 2016 Irish Times Best Crime Novel of 2016 for Rain Dogs 2016 Theakston Old Peculier Crime Novel of the Year Award shortlist for Rain Dogs 2016 Ned Kelly Award shortlist for Rain Dogs 2016 CWA Ian Fleming Steel Dagger shortlist for Rain Dogs 2017 Edgar Award (Best Paperback Original) for Rain Dogs 2017 Barry Award for Rain Dogs 2017 Anthony Award (Best Paperback Original) for Rain Dogs 2017 Ned Kelly Award for Police at the Station and They Don't Look Friendly 2017 CWA Ian Fleming Steel Dagger Award shortlist for Police at the Station and They Don't Look Friendly 2017 Boston Globe Best Book of 2017 for Police at the Station and They Don't Look Friendly 2018 International Thriller Writers Awards (Best Paperback Original Novel) shortlist for Police at the Station and They Don't Look Friendly 2019 Time magazine Books of the Year for The Chain 2020 Theakston's Old Peculier Crime Novel of the Year Award 2020 winner for The Chain. 2020 Ian Fleming Steel Dagger Award longlist for The Chain; CWA Body in the Library longlist for The Chain 2020 International Thriller Writers Award for Best Hardcover Novel, The Chain. 2020 Ned Kelly Award for Best International Crime Fiction for The Chain. 2020 Macavity Awards for Best Mystery Novel by Mystery Readers International for The Chain. 2020 Barry Award (for crime novels) for Best Mystery Novel winner for The Chain. 2022 In The Morning I'll Be Gone winner of the Prix Polar Pourpres for Best Mystery Novel 2022 Best Thrillers of 2022 for The Island. New York Times 2023 Best Thrillers of 2023 for The Detective Up Late. Washington Post 2024 Barry Award (for crime novels) nominee for Best Mystery Novel for The Detective Up Late
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.